Cargando…
Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis
BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown promising efficacy in treatment and clinical management of advanced gastric and gastroesophageal junction cancer. However, the inhibitors also cause immune-related adverse events (irAEs). The current systematic review and meta-analysis study...
Autores principales: | Pei, Wen-Guang, Chen, Wen-Zheng, Wu, Yu-Kang, Tan, Sheng-Xing, Jie, Zhi-Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994050/ https://www.ncbi.nlm.nih.gov/pubmed/36908315 http://dx.doi.org/10.4251/wjgo.v15.i2.352 |
Ejemplares similares
-
Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis
por: Nso, Nso, et al.
Publicado: (2020) -
Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis
por: Zhang, Shuo, et al.
Publicado: (2021) -
Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis
por: Liu, Tingting, et al.
Publicado: (2020) -
Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017) -
Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
por: Yang, Li, et al.
Publicado: (2020)